Study suggests H3.1 biomarker may help assess sepsis in ICU patients

Published 12/06/2025, 13:38
Study suggests H3.1 biomarker may help assess sepsis in ICU patients

HENDERSON, Nev. - VolitionRx Limited (NYSE AMERICAN: VNRX), a $58 million market cap diagnostic company showing 64% revenue growth in the last twelve months according to InvestingPro data, reported Thursday that a peer-reviewed clinical study suggests its Nu.Q H3.1 biomarker could potentially inform clinical care for critically ill patients by assessing sepsis, organ failure and inflammatory responses.

The study, involving 1,713 intensive care unit patients, examined the relationship between H3.1 nucleosome concentrations and clinical outcomes. Researchers collected plasma samples on days 0, 2, and 4, totaling 3,671 samples.

According to the publication, patients with acute kidney injury, disseminated intravascular coagulation, and acute respiratory distress syndrome showed significantly higher Nu.Q H3.1 levels compared to those without these conditions.

Dr. Andrew Retter, Chief Medical Officer at Volition, described the biomarker as "clinically meaningful" and "biologically specific" for measuring NETosis, a cellular process related to immune response.

Lieuwe D.J. Bos, PhD, Principal Investigator at Amsterdam University Medical Center and senior author of the study, stated that plasma nucleosomes represented by H3.1 concentration "are associated with the presence of sepsis, the severity of organ dysfunction, and a hyperinflammatory host response."

The study positions the assay not as a traditional diagnostic tool but as a potential instrument for prognostic assessment and therapeutic monitoring. While the company shows promising technological developments, InvestingPro analysis indicates the company is currently burning through cash rapidly, with a current ratio of 0.4 suggesting potential liquidity challenges ahead.

Volition, a multi-national epigenetics company, focuses on developing blood tests for disease detection and monitoring. The company conducts research primarily in Belgium, with additional facilities in the United States and London.

The information is based on a company press release statement.

In other recent news, VolitionRX Limited reported its first-quarter 2025 financial results, revealing a larger-than-expected loss per share and a revenue shortfall. The company posted an earnings per share (EPS) of -$0.06, missing the forecasted -$0.04, and revenue of $250,000, significantly below the expected $1.31 million. Despite these financial misses, VolitionRX is focusing on reducing operational costs, which declined by 35% from the previous year, and advancing its Nu.Q platform in the human diagnostic market. Jones Trading initiated coverage of VolitionRX with a Buy rating and set a price target of $3.00, citing potential growth opportunities and strategic partnerships in the human health arena. Meanwhile, Benchmark maintained a Hold rating, highlighting the company’s focus on licensing agreements and expanding its veterinary testing division. VolitionRX is also working on multiple licensing agreements in the human diagnostic space, with discussions underway with several pharmaceutical companies. The company aims to be cash neutral by the end of 2025 and is pursuing various initiatives to bolster its market presence and revenue.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.